# US 2021/0277101 A1 · Humanized anti-s100a9 antibody and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0277101 A1 - Document ID: US20210277101A1 - Status: Published application - Kind: A1 - Application number: 16/316,146 - Filed: 2016-07-11 - Published: 2021-09-09 - Earliest claimed: 2015-07-13 - Assignees: Universite Laval - Applicants: UNIVERSITE laval - Inventors: Philippe TESSIER; Mélanie TARDIF; Traian SULEA - Web page: https://patentgrep.com/patent/US20210277101A1 ## CPC - C07K 16/24: against cytokines, lymphokines or interferons - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61P 37/00: Drugs for immunological or allergic disorders - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/567: Framework region [FR] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor. ## Claims ### Claim 1 An inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2). ### Claim 2 (depends on 1) The inhibitor of claim 1, wherein the inhibitor is an antibody that specifically binds to an epitope of S100A9 protein. ### Claim 3 (depends on 1) The inhibitor of claim 1, adapted to inhibit binding of said S100A9 protein to TLR2. ### Claim 4 (depends on 1) The inhibitor of claim 1, which is an anti-S100A9 antibody. ### Claim 5 (depends on 4) The inhibitor of claim 4, wherein said anti-S100A9 antibody is a mouse antibody or a humanized antibody. ### Claim at position 6 6-7. (canceled) ### Claim 8 (depends on 4) The inhibitor of claim 4, wherein said antibody comprises an epitope binding to the C-terminal region or the hinge region of the S100A9 protein. ### Claim 9 (depends on 4) The inhibitor of claim 4, wherein said antibody comprises an epitope binding to the 10 last amino acids of the C-terminal region of the S100A9 protein. ### Claim 10 (canceled) ### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10) The inhibitor of any one of claims 4-10, wherein said antibody recognizes a unique epitope on the S100A9 molecule defined as LGxxTx (SEQ ID NO: 70), LGExTP (SEQ ID NO: 71), PGLGExTP (SEQ ID NO: 72), or PGLGEGTP (SEQ ID NO: 67). ### Claim at position 11 12-14. (canceled) ### Claim 15 (depends on 5) The inhibitor of claim 5, wherein said antibody comprises a chain selected from the group consisting of: SEQ ID NO: 2, 21, 22, 23, 25 and 41. ### Claim 16 (canceled) ### Claim 17 (depends on 5) The inhibitor of claim 5, wherein said antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 42, 43, 44, 45, 46, 47 and 48. ### Claim 18 An antibody comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, 21, 22, 23, 25, 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 48. ### Claim at position 16 19-30. (canceled) ### Claim 31 (depends on 1) A method for treating an inflammatory condition comprising the step of administering to a subject in need thereof an effective amount of the inhibitor of claim 1. ### Claim 32 (depends on 31) The method of claim 31, wherein said inflammatory condition is selected from the group consisting of: rheumatoid arthritis, asthma, gout, type I diabetes, Crohn's disease, lupus erythematosus, multiple sclerosis, inflammatory bowel disease (IBD), ulcerative colitis, chronic inflammation, psoriasis, and cancer metastasis. ### Claim 33 (depends on 31) The method of claim 31, wherein said inflammatory condition is a chronic inflammatory disease. ### Claim 34 (depends on 33) The method of claim 33, wherein said chronic inflammatory disease is pyogenic arthritis, pyoderma gangrunosum, acnea syndrome, adult-onset Still's disease, or systemic-onset juvenile idiopathic arthritis. ### Claim 35 (depends on 31) The method of claim 31, wherein said inflammatory condition is rheumatoid arthritis. ### Claim 36 (depends on 31) The method of claim 31, wherein said inhibitor is administered to a mammal. ### Claim 37 (depends on 36) The method of claim 36, wherein said mammal is a human. ### Claim 38 (depends on 31) The method of claim 31, wherein said inhibitor is administered subcutaneously, intravenously, intramuscularly, intra-articular or intraperitoneally.